E-therapeutics Plc

ETXPFOTCHealthcare

$0.13

+$0.00(+0.00%)

Market Cap$75963547

P/E Ratio—

52W High$0.13

52W Low$0.13

Avg Volume993

Open$0.13

Beta0.42

Overview

E-therapeutics Plc (ETXPF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ETXPF · free cash flow · updated Jun 15, 2026

Core FCF metrics

ETXPF · FCF · TTM · margin & CAGR

Free cash flow was −$17.0M for FY2025 (fiscal year ending 2025-01-31), down 52.3% year-over-year

FY2025 Free Cash Flow−$17.0M▼ -52.3% YoY

Trailing 12M (TTM)−$27.4Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ETXPF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$16.6M(0M)−$17.0M▼ 52.3%—

FY2024−$10.9M(0M)−$11.1M▼ 35.6%—

FY2023−$8.0M(0M)−$8.2M▲ +29.8%—

FY2022−$10.4M(1M)−$11.7M▼ 150.0%—

FY2021−$4.6M(0M)−$4.7M▼ 75.3%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ETXPF · P/FCF · FCF yield · FCF per share

E-therapeutics Plc (ETXPF) reported negative free cash flow of −$0.02B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-01-31

Cash flow statement summary

ETXPF · cash flow statement · operating / investing / financing

For FY2025, E-therapeutics Plc generated −$16.6M in operating cash flow and spent 0M in capital expenditures, yielding −$17.0M in free cash flow.

Operating Activities

−$16.6M

Cash from core business operations

2025-01-31

Investing Activities

−$12.1M

CapEx, acquisitions & investments

2025-01-31

Financing Activities

+$28.5M

Buybacks, dividends & debt

2025-01-31

FCF FormulaOperating CF (−$16.6M) − |CapEx| (0M) = FCF (−$17.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ETXPF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

E-therapeutics PlcYOU

ETXPF

−$17.0M-52.3%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

E-therapeutics Plc (ETXPF) reported free cash flow of −$17.0M for FY2025 (fiscal year ending 2025-01-31), down 52.3% year-over-year.

E-therapeutics Plc has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ETXPF free cash flow · 8 questions

E-therapeutics Plc free cash flow was −$17.0M for FY2025, down 52.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$27.4M.

ETXPF free cash flowETXPF FCFETXPF FCF 2025ETXPF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · E-therapeutics Plc · E-therapeutics Plc SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026